Inventiva SA
PAR:IVA
Inventiva SA
Revenue
Inventiva SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Revenue
€15.6m
|
CAGR 3-Years
255%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Revenue
€169.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
Nanobiotix SA
PAR:NANO
|
Revenue
€36.2m
|
CAGR 3-Years
1 063%
|
CAGR 5-Years
242%
|
CAGR 10-Years
70%
|
|
|
Innate Pharma SA
PAR:IPH
|
Revenue
€24.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
11%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Revenue
€84m
|
CAGR 3-Years
151%
|
CAGR 5-Years
61%
|
CAGR 10-Years
29%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Revenue
€144.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
Inventiva SA
Revenue Breakdown
Breakdown by Geography
Inventiva SA
|
Total Revenue:
17.5m
EUR
|
|
Japan:
12.8m
EUR
|
|
China:
4.6m
EUR
|
|
France:
118k
EUR
|
Breakdown by Segments
Inventiva SA
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Revenue?
Revenue
15.6m
EUR
Based on the financial report for Jun 30, 2024, Inventiva SA's Revenue amounts to 15.6m EUR.
What is Inventiva SA's Revenue growth rate?
Revenue CAGR 5Y
37%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Inventiva SA have been 255% over the past three years , 37% over the past five years .
You don't have any saved screeners yet